Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBT Margin (2019 - 2026)

C4 Therapeutics has reported EBT Margin over the past 8 years, most recently at 408.47% for Q1 2026.

  • For Q1 2026, EBT Margin fell 4480.0% year-over-year to 408.47%; the TTM value through Mar 2026 reached 297.41%, down 3814.0%, while the annual FY2025 figure was 291.74%, 385.0% up from the prior year.
  • EBT Margin for Q1 2026 was 408.47% at C4 Therapeutics, down from 184.87% in the prior quarter.
  • Over five years, EBT Margin peaked at 147.56% in Q2 2024 and troughed at 1348.42% in Q2 2023.
  • A 5-year average of 558.95% and a median of 408.47% in 2026 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: plummeted -122492bps in 2022 and later surged 120086bps in 2024.
  • Year by year, EBT Margin stood at 1302.91% in 2022, then rose by 19bps to 1057.25% in 2023, then soared by 37bps to 665.29% in 2024, then surged by 72bps to 184.87% in 2025, then crashed by -121bps to 408.47% in 2026.
  • Business Quant data shows EBT Margin for CCCC at 408.47% in Q1 2026, 184.87% in Q4 2025, and 286.43% in Q3 2025.